七月 2026
- Home
- ExcellGene
七月 2026的ExcellGene市场份额分析
Discover cutting-edge CHO and HEK293 manufacturing solutions. Accelerate and de-risk recombinant biologic drug development with our high-yield, fast, and scalable production technologies.
ExcellGene(包含公司地区分支机构)
查看更多网站流量和参与度信息- excellgene.com
ExcellGene收入截至 七月 2026为 2M - 5M
ExcellGene主要域名产生的收入
3 年中ExcellGene主要域名的收入
ExcellGene主要域名的收入
ExcellGene热门域名的总访问量
了解ExcellGene市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
ExcellGene热门域名的平均访问时长
分析ExcellGene参与度指标。
过去 3 个月的平均访问时长
子公司明细
ExcellGene热门域名的平均页面浏览量
了解ExcellGene如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
ExcellGene 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Excellgene SA partnered with Cytovance® Biologics, Inc. on May 8th '24.OKLAHOMA CITY, Oklahoma, MONTHEY, Switzerland, May 8, 2024 - ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
五月 8, 2024阅读更多
新闻Lottebiologics partners with Excellgene SA.“Through this meaningful agreement with EXCELLGENE, which has experience in projects with leading global biopharmaceutical companies, Lottebiologics will bolster its competitive bidding capabilities of CDMO”
四月 2, 2023阅读更多
新闻Excellgene SA is developing variant-proof SARS-CoV-2 vaccine on Jan 4th '22.Bharat Biotech also announced last year that along with Switzerland’s ExcellGene SA and University of Sydney it was going to develop a variant-proof SARS-CoV-2 vaccine that was being funded through CEPI (the Coalition for Epidemic Preparedness Innovations).
一月 4, 2023阅读更多
查看 ExcellGene 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
